How I treat patients with advanced systemic mastocytosis.

Advanced systemic mastocytosis (SM) is a rare myeloid neoplasm characterized by uncontrolled accumulation of neoplastic mast cells (MCs) in various organs with consecutive impairment of organ function, drug resistance, and a poor prognosis. Advanced SM may present as smoldering or slowly progressing neoplasm but may also present as rapidly progressing aggressive SM or even as MC leukemia. Approximately half of the patients have an associated hematologic non-MC-lineage disease (SM-AHNMD) or develop an AHNMD over time. Drug resistance may not only result from the KIT mutant D816V that is found in most patients, but also from KIT-independent pro-oncogenic signaling pathways that play a role in disease evolution. In patients with slow progression, advanced SM can often be kept under control for months with interferon-α or 2CdA. By contrast, in rapidly progressing aggressive SM and MC leukemia, even polychemotherapy and hematopoietic stem cell transplantation may fail, which points to the need to develop new drugs and treatment concepts for these patients. In SM-AHNMD, separate treatment plans should be established for the SM component and the AHNMD component of the disease, with recognition that the AHNMD often has to be managed and treated as a secondary and thus a high-risk neoplasm.

[1]  K. Sotlar,et al.  Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis , 2011, Modern Pathology.

[2]  H. Pehamberger,et al.  In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. , 2010, Experimental hematology.

[3]  T. George,et al.  Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. , 2010, Best practice & research. Clinical haematology.

[4]  K. Sotlar,et al.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V , 2010, Molecular oncology.

[5]  K. Sotlar,et al.  Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review , 2010, Pathobiology.

[6]  K. Sotlar,et al.  Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD) , 2010, The Journal of pathology.

[7]  A. Tefferi,et al.  Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature , 2010, Current opinion in hematology.

[8]  K. Sotlar,et al.  Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis A Distinct Subtype of Systemic Mastocytosis-Associated Clonal Hematological Nonmast Cell Lineage Disorder Carrying the Activating Point Mutations KIT D816V and JAK2 V617F , 2010 .

[9]  A. Tefferi,et al.  Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosine , 2009, American journal of hematology.

[10]  A. Tefferi,et al.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.

[11]  E. Jassem,et al.  Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy , 2009, Allergy.

[12]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[13]  P. Valent,et al.  Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis , 2008, European journal of clinical investigation.

[14]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[15]  H. Kantarjian,et al.  Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis , 2008, Clinical Cancer Research.

[16]  R. Sinniah,et al.  Dasatinib therapy for systemic mastocytosis: four cases , 2008, European journal of haematology.

[17]  M. Fernández-Rivas,et al.  Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. , 2008, The Journal of allergy and clinical immunology.

[18]  F. Sim,et al.  Mastocytosis (Mast Cell Disease) , 2008 .

[19]  K. Sotlar,et al.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. , 2008, The Journal of molecular diagnostics : JMD.

[20]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[21]  K. Sotlar,et al.  Mastocytosis: State of the Art , 2007, Pathobiology.

[22]  P. Valent,et al.  FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis , 2007, European journal of clinical investigation.

[23]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[24]  P. Valent,et al.  Pathogenesis, clinical features, and treatment advances in mastocytosis. , 2006, Best practice & research. Clinical haematology.

[25]  J. Gotlib.  KIT mutations in mastocytosis and their potential as therapeutic targets. , 2006, Immunology and allergy clinics of North America.

[26]  C. Chen,et al.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.

[27]  K. Sotlar,et al.  Mastocytosis: Pathology, genetics, and current options for therapy , 2005, Leukemia & lymphoma.

[28]  M. Landthaler,et al.  ["Smoldering systemic mastocytosis. "Successful therapy with cladribine]. , 2004, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[29]  Cem Akin,et al.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. , 2004, Blood.

[30]  M. Uffmann,et al.  Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. , 2004, Leukemia research.

[31]  H. Kluin-Nelemans,et al.  Cladribine therapy for systemic mastocytosis. , 2003, Blood.

[32]  J. Bennett,et al.  Diagnosis and treatment of systemic mastocytosis: state of the art , 2003, British journal of haematology.

[33]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[34]  J. Bennett,et al.  Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. , 2003, Leukemia research.

[35]  P. Valent,et al.  A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. , 2002, Leukemia research.

[36]  Shan Zeng,et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.

[37]  P. Valent,et al.  Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression , 2002, International Archives of Allergy and Immunology.

[38]  P. Valent,et al.  Kit and c-kit Mutations in Mastocytosis: A Short Overview with Special Reference to Novel Molecular and Diagnostic Concepts , 2002, International Archives of Allergy and Immunology.

[39]  P. Valent,et al.  Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis , 2002, International Archives of Allergy and Immunology.

[40]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[41]  L. Scott,et al.  Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case? , 2001, Leukemia research.

[42]  A. Chott,et al.  A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. , 2001, Leukemia research.

[43]  P. Valent,et al.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.

[44]  P. Valent,et al.  Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.

[45]  A. Tefferi,et al.  Treatment of systemic mast-cell disease with cladribine. , 2001, The New England journal of medicine.

[46]  H. Griesser,et al.  Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia , 2000, Molecular pathology : MP.

[47]  Butterfield Jh.  Response of severe systemic mastocytosis to interferon alpha. , 1998 .

[48]  Butterfield.  Response of severe systemic mastocytosis to interferon alpha , 1998, The British journal of dermatology.

[49]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[50]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  H. Kluin-Nelemans,et al.  Response to interferon alfa-2b in a patient with systemic mastocytosis. , 1992, The New England journal of medicine.

[52]  D. Metcalfe.  The liver, spleen, and lymph nodes in mastocytosis. , 1991, Journal of Investigative Dermatology.

[53]  D. Metcalfe,et al.  Splenectomy in the management of systemic mast cell disease. , 1990, Surgery.